NasdaqGS - Delayed Quote USD

Gossamer Bio, Inc. (GOSS)

1.3300

+0.0700

+(5.56%)

At close: June 6 at 4:00:01 PM EDT

1.3193

-0.01

(-0.80%)

After hours: June 6 at 7:19:19 PM EDT

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 06, 2025--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective June 5th, 2025, to three non-executive employees of non-qualified stock optio

Business Wire yesterday

GOSS
+5.56%
Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

MIAMI, May 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies

GlobeNewswire 18 days ago

GOSS
+5.56%

RGBP

RGBPP
Gossamer Bio Inc (GOSS) Q1 2025 Earnings Call Highlights: Strategic Progress Amid Financial ...

Gossamer Bio Inc (GOSS) reports strong cash reserves and strategic advancements in clinical trials, despite a net loss and delayed study results.

GuruFocus.com 23 days ago

GOSS
+5.56%
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates

Gossamer Bio (GOSS) delivered earnings and revenue surprises of 11.11% and 167.27%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 23 days ago

GOSS
+5.56%
Gossamer Bio: Q1 Earnings Snapshot

SAN DIEGO (AP) — Gossamer Bio Inc. GOSS) on Thursday reported a loss of $36.6 million in its first quarter. The San Diego-based company said it had a loss of 16 cents per share.

Associated Press Finance 23 days ago

GOSS
+5.56%
Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

SAN DIEGO, May 15, 2025--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 2025, and announced the closure of new patient screening for the ongoing registrational Phase 3 PROSERA Study in

Business Wire 23 days ago

GOSS
+5.56%
Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

SAN DIEGO, May 12, 2025--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it will report its first quarter 2025 financial results on Thursday, May 15, 2025.

Business Wire 26 days ago

GOSS
+5.56%
Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

SAN DIEGO, May 07, 2025--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present a poster at the American Thoracic Society (ATS) 2025 International Conference, taking place from May 16th through 21st, in San Francisco, California.

Business Wire last month

GOSS
+5.56%
3 Promising Penny Stocks With Market Caps Over $100M

Stocks in the United States have been mixed recently, with gains tempered by ongoing tariff uncertainties and varying corporate earnings reports. For investors willing to explore beyond the well-known names, penny stocks—often associated with smaller or newer companies—can still offer intriguing opportunities. Despite being a somewhat outdated term, these stocks remain relevant as they present potential for growth at lower price points when supported by strong balance sheets and solid...

Simply Wall St. last month

QSG

VGZ

GOSS
+5.56%
Pleasing Signs As A Number Of Insiders Buy Gossamer Bio Stock

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Simply Wall St. last month

GOSS
+5.56%
Is Gossamer Bio Inc. (NASDAQ:GOSS) the Best Penny Stock to Invest in Under $1?

We recently published a list of the 11 Best Penny Stocks to Invest in Under $1. In this article, we are going to take a look at where Gossamer Bio Inc. (NASDAQ:GOSS) stands against other penny stocks to invest in under $1. Earlier on February 12 this year, Chief Investment Officer at Cetera Financial Group, […]

Insider Monkey last month

GOSS
+5.56%
Gossamer Bio, Inc. (GOSS): Among Stocks Under $10 that Will Triple

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Gossamer Bio, Inc. (NASDAQ:GOSS) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]

Insider Monkey last month

GOSS
+5.56%
Is Gossamer Bio Inc. (GOSS) the Popular Penny Stock on Robinhood to Watch?

We recently published a list of 12 Popular Penny Stocks on Robinhood to Watch. In this article, we are going to take a look at where Gossamer Bio Inc. (NASDAQ:GOSS) stands against other popular penny stocks on Robinhood to watch. The stock market is navigating a complex landscape influenced by geopolitical tensions, trade policies, and […]

Insider Monkey 2 months ago

GOSS
+5.56%

HOOD
Is Gossamer Bio, Inc. (GOSS) The Hot Biotech Stock Under $5?

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Gossamer Bio, Inc. (NASDAQ:GOSS) stands against other hot biotech stocks under $5. The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention. After a […]

Insider Monkey 2 months ago

GOSS
+5.56%
Gossamer Bio (GOSS): Among the Penny Stocks With Huge Upside Potential According to Analysts

We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are going to take a look at where Gossamer Bio, Inc. (NASDAQ:GOSS) stands against other penny stocks with the biggest upside potential. Penny stocks trade below $5 and attract investors looking for high returns with […]

Insider Monkey 2 months ago

GOSS
+5.56%
Gossamer Bio (GOSS) Reports Q4 Loss, Tops Revenue Estimates

Gossamer Bio (GOSS) delivered earnings and revenue surprises of 11.76% and 19.63%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

GOSS
+5.56%
Gossamer Bio: Q4 Earnings Snapshot

On a per-share basis, the San Diego-based company said it had a loss of 15 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 17 cents per share.

Associated Press Finance 2 months ago

GOSS
+5.56%
Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

SAN DIEGO, March 13, 2025--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December 31, 2024, and provided a business update.

Business Wire 2 months ago

GOSS
+5.56%
3 Promising Penny Stocks With Over $100M Market Cap

As the U.S. stock market faces a sell-off driven by concerns over tariffs and economic uncertainty, investors are increasingly looking for opportunities that can offer resilience and potential growth. Penny stocks, while often associated with risk due to their smaller size and less-established nature, still hold promise when they are backed by strong financials. In this article, we explore three penny stocks that exhibit solid balance sheets and the potential for long-term value creation...

Simply Wall St. 2 months ago

GOSS
+5.56%

SLRN

KNDI
With 60% ownership of the shares, Gossamer Bio, Inc. (NASDAQ:GOSS) is heavily dominated by institutional owners

Key Insights Significantly high institutional ownership implies Gossamer Bio's stock price is sensitive to their...

Simply Wall St. 3 months ago

GOSS
+5.56%

Performance Overview

Return	GOSS	S&P 500 (^GSPC)
YTD	+46.96%	+2.02%
1-Year	+121.67%	+12.09%
3-Year	-80.24%	+45.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Gossamer Bio, Inc. (GOSS)

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

Gossamer Bio Inc (GOSS) Q1 2025 Earnings Call Highlights: Strategic Progress Amid Financial ...

Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates

Gossamer Bio: Q1 Earnings Snapshot

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

3 Promising Penny Stocks With Market Caps Over $100M

Pleasing Signs As A Number Of Insiders Buy Gossamer Bio Stock

Is Gossamer Bio Inc. (NASDAQ:GOSS) the Best Penny Stock to Invest in Under $1?

Gossamer Bio, Inc. (GOSS): Among Stocks Under $10 that Will Triple

Is Gossamer Bio Inc. (GOSS) the Popular Penny Stock on Robinhood to Watch?

Is Gossamer Bio, Inc. (GOSS) The Hot Biotech Stock Under $5?

Gossamer Bio (GOSS): Among the Penny Stocks With Huge Upside Potential According to Analysts

Gossamer Bio (GOSS) Reports Q4 Loss, Tops Revenue Estimates

Gossamer Bio: Q4 Earnings Snapshot

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

3 Promising Penny Stocks With Over $100M Market Cap

With 60% ownership of the shares, Gossamer Bio, Inc. (NASDAQ:GOSS) is heavily dominated by institutional owners

Performance Overview